Use of Favipiravir in treatment of COVID-19 | Indian Phase 3 Clinical Trial Outcomes

Use of Favipiravir in treatment of COVID-19 | Indian Phase 3 Clinical Trial Outcomes

Coronavirus, Therapeutic

1 Hour 30 Minutes

English Site


Course Overview

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that was declared a global pandemic in March 2020 by the WHO. During the time since it emerged into a global crisis, there have been several recommendations to prevent spread of infection and to manage COVID-19 infected patients through supportive care, plasma therapy, oxygen support, and support of other affected vital organs.

Treatment options for COVID-19 are now emerging through several global clinical trials on antivirals, and the Indian Medical Association (Maharasthra) welcomes you to a live webinar to understand the use of antiviral Favipiravir in treatment of COVID-19 patients. During this webinar supported by Glenmark Pharmaceuticals, phase 3 clinical trial (CT) outcomes with Flavipiravir will be presented for the information of health care professionals.  

The key points discussed during webinar will be as follows:

Antivirals in COVID-19

  • Why treatment with antiviral is a key?
  • Timing of antiviral treatment-  Hit Early, Hit Hard

Favipiravir Snapshot

  • Molecule Profile
  • Current Global Status

Indian RCT – Topline Results

  • Study design
  • Efficacy Outcomes
  • Safety Outcomes



Introduction & context Setting (5 Mins)
Dr. Sagar Panchal (M.B.B.S, M.D (Pharmacology))

Favipiravir in treatment of Covid-19 | Indian Phase 3 CT Outcomes (40 Mins)
Dr. Sagar Panchal (M.B.B.S, M.D (Pharmacology)

Panel Discussion, Q & A (40 min)
Dr. Swami Pawar (MBBS, MD Chest)
Dr. Swapnil Gautam (MBBS, MD, DNB, MNAMS, PGDMLS)

Summary  & Vote of thanks (5 mins)
Dr. Sagar Panchal (M.B.B.S, M.D (Pharmacology)
Dr Avinash Bhondwe (IMA-MS President)
Dr Pankaj Bandarkar (IMA-MS Hon Secretary)

Coming session Starts Aug 06, 2020
Ends Oct 06, 2020